Burkhard Schmidt

Medical Genetics Center — Germany

Health Professions · Health Sciences

30h-index3.1kcitations159works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Workplace Health and Well-being(19), Chronic Lymphocytic Leukemia Research(15), Acute Myeloid Leukemia Research(14), Lymphoma Diagnosis and Treatment(12), Pleural and Pulmonary Diseases(12)

Publications158 total

Ixazomib maintenance therapy in transplant-eligible multiple myeloma: real-world evidence from three large German centers
Haematologica·2025· 1 citedOpen Access
Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo‐Controlled Phase 2 <scp>DELTA</scp> Trial
American Journal of Hematology·2025Open Access
How I diagnose and treat patients in the pre-fibrotic phase of primary myelofibrosis (pre-PMF) - practical approaches of a German expert panel discussion in 2024
Annals of Hematology·2025· 4 citedOpen Access
Clinical Outcomes of CLL Patients Treated with Venetoclax Under Real-World Conditions in Austria, Germany, and Switzerland after Treatment with Ibrutinib
Blood·2024· 1 cited
Einleitung einer tumorspezifischen Therapie auf der Intensivstation – eine kontroverse Therapieentscheidung
Pneumologie·2024
Sicherheit und Komplikationen der bronchoskopischen Ventilimplantation bei Patient*innen mit fortgeschrittenem Lungenemphysem und hochgradig eingeschränktem 6-Minuten Gehtest≤140m
Pneumologie·2024· 1 cited
Lobektomie oder Shaving zur operativen Lungenvolumenreduktion – Analyse der Daten des Lungenemphysemregisters
Pneumologie·2024Open Access
Safety and Effectiveness in Treatment Naive CLL Patients with or without High Risk Features Treated with Veno Under Real-World Conditions in Austria, Germany, and Switzerland
Blood·2023
P554: RESULTS OF A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 STUDY OF HYPOMETHYLATING AGENTS WITH OR WITHOUT ELTROMBOPAG IN ELDERLY AML PATIENTS (DELTA)
HemaSphere·2023Open Access
Lobektomie oder Shaving zur operativen Lungenvolumenreduktion, welches Verfahren ist überlegen? – Eine Analyse der Daten des Lungenemphysemregisters
Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie·2023Open Access
Improving Health and Reducing Absence Days at Work: Effects of a Mindfulness- and Skill-Based Leadership Intervention on Supervisor and Employee Sick Days
Mindfulness·2023· 3 citedOpen Access
SAFETY AND EFFECTIVENESS IN R/R CLL PATIENTS TREATED WITH VENETOCLAX IN COMBINATION WITH RITUXIMAB UNDER REAL‐WORLD CONDITIONS IN AUSTRIA, GERMANY, AND SWITZERLAND
Hematological Oncology·2023Open Access
Bronchoskopische Dampfablation (BTVA) – Lungenfunktion und Lebensqualität nach 3 Monaten – 54 Fälle des nationalen Lungenemphysemregisters
Pneumologie·2023
Lungenvolumenreduktion mit Einweg-Ventilen bei fortgeschrittenem Lungenemphysem bei Alpha-1-Antitrypsin-Mangel: Ergebnisse aus dem Lungenemphysemregister e.V.
Pneumologie·2023
Inhalative Therapie der COPD als Vulnerabilitätsfaktor hitzeassoziierter Exazerbationen – eine prospektive Studie im urbanen Berlin
Pneumologie·2023· 1 cited
Der pulmonale Rundherd: nicht immer Krebs! IgG4 assoziierte Erkrankung als seltene Differentialdiagnose
Pneumologie·2023
Elevated RIPK3 correlates with disease burden in myelofibrosis
Blood Advances·2022Open Access
Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma
Blood·2022· 16 citedOpen Access
Real-World Effectiveness and Safety of Venetoclax in Combination with Obinutuzumab in Treatment-Naive CLL Patients - Data from the Observational Study Verve
Blood·2022· 1 cited
P647: SAFETY AND EFFECTIVENESS OF VENETOCLAX MONOTHERAPY IN R/R CLL PATIENTS WITH OR WITHOUT RISK-ASSOCIATED GENETIC MARKERS – DATA FROM THE OBSERVATIONAL VERVE STUDY
HemaSphere·2022Open Access
page 1 of 8Next →

Frequent Co-authors

Christian Peschel(12), Raphael M. Herr(11), Marc N. Jarczok(8), Adrian Loerbroks(8), Joachim E. Fischer(8), Helga Bernhard(6), Jos A. Bosch(6), Katharina S. Götze(5), A.E.M. van Vianen(5), Dirk H. Busch(4), Jian Li(4), Catharina Müller‐Thomas(4), Markus Schwaiger(3), Ingo Drexler(3), Gerd Sutter(3), Daniel Mauss(3), Christian Meyer zum Büschenfelde(3), Stefanie Jilg(3), Ulrike Höckendorf(3), Philipp J. Jost(3)